← Back to Search

Monoclonal Antibodies

C144-LS and C-135-LS for Coronavirus (RU Trial)

Phase 1
Waitlist Available
Led By Christian Gaebler, MD
Research Sponsored by Rockefeller University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights

RU Trial Summary

This study is evaluating whether a combination of two antibodies can be safely given to people with COVID-19.

Eligible Conditions
  • Coronavirus

RU Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Lateral Septal Nucleus
Clearance rate of C135-LS and C144-LS
Elimination half-life (t1/2) of C135-LS and C144-LS
+3 more
Secondary outcome measures
Droxidopa
Investigational New Drugs
Serum neutralizing activity against SARS-CoV-2

RU Trial Design

5Treatment groups
Experimental Treatment
Group I: V3 - high doseExperimental Treatment1 Intervention
15 mg/kg of C144-LS and 15 mg/kg of C135-LS, intravenously
Group II: V2 - mid doseExperimental Treatment1 Intervention
5 mg/kg of C144-LS and 5 mg/kg of C135-LS, intravenously
Group III: V1 - low doseExperimental Treatment1 Intervention
1.5 mg/kg of C144-LS and 1.5 mg/kg of C135-LS, intravenously
Group IV: S2 - mid doseExperimental Treatment1 Intervention
200 mg of C144-LS and 200 mg of C135-LS, subcutaneously
Group V: S1 - low doseExperimental Treatment1 Intervention
100 mg of C144-LS and 100 mg of C135-LS, subcutaneously
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
C144-LS and C-135-LS
2021
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Rockefeller UniversityLead Sponsor
158 Previous Clinical Trials
16,334 Total Patients Enrolled
Christian Gaebler, MDPrincipal InvestigatorThe Rockefeller University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
NatureJournal
Convergent Antibody Responses to Sars-cov-2 in Convalescent Individuals
Robbiani, Davide F., Christian Gaebler, Frauke Muecksch, Julio C. C. Lorenzi, Zijun Wang, Alice Cho, Marianna Agudelo, et al.. 2020. “Convergent Antibody Responses to Sars-cov-2 in Convalescent Individuals”. Nature. Springer Science and Business Media LLC. doi:10.1038/s41586-020-2456-9.
clinicaltrials.govStudy
RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
2021. "RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04700163.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top